RA Capital Management’s Aclaris Therapeutics ACRS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$66.9M Hold
12,723,026
– – 0.67% 32
2026
Q2
$67.3M Buy
12,723,026
+5,918,954
+87% +$26.4M 0.58% 33
2026
Q1
$25.5M Buy
+6,804,072
New +$23M 0.27% 52
2025
Q2
– Sell
-4,666,667
Closed -$7.14M – 64
2025
Q1
$7.14M Hold
4,666,667
– – 0.12% 71
2024
Q4
$11.6M Buy
+4,666,667
New +$11.6M 0.15% 71
2023
Q4
– Sell
-4,398,453
Closed -$30.1M – 63
2023
Q3
$30.1M Hold
4,398,453
– – 0.59% 44
2023
Q2
$45.6M Hold
4,398,453
– – 0.86% 34
2023
Q1
$35.6M Hold
4,398,453
– – 0.81% 38
2022
Q4
$69.3M Hold
4,398,453
– – 1.41% 24
2022
Q3
$69.2M Hold
4,398,453
– – 1.48% 21
2022
Q2
$61.4M Buy
4,398,453
+2,580,645
+142% +$36.2M 1.64% 17
2022
Q1
$31.3M Buy
+1,817,808
New +$24.8M 0.68% 45
2016
Q4
– Sell
-1,547,152
Closed -$39.6M – 28
2016
Q3
$39.6M Sell
1,547,152
-1,080,567
-41% -$22.9M 4.09% 8
2016
Q2
$48.5M Hold
2,627,719
– – 6.72% 5
2016
Q1
$49.8M Buy
2,627,719
+63,166
+2% +$1.21M 6.36% 4
2015
Q4
$69.1M Buy
+2,564,553
New +$50M 6.84% 5

Other funds holding ACRS

RA Capital Management's ACRS Position: Q3 2026 in Review

RA Capital Management held its Aclaris Therapeutics (ACRS) position steady in Q3 2026 at 12,723,026 shares worth $66.9M. The position accounts for 0.67% of the portfolio, ranked #32.

RA Capital Management first reported a position in ACRS in Q4 2015 and has held it in 16 quarters since. The position peaked at $69.3M in Q4 2022. 163 funds tracked by Wall St. Rank hold ACRS as of Q3 2026.

  • RA Capital Management held 12,723,026 shares of Aclaris Therapeutics worth $66.9M as of Q3 2026.
  • RA Capital Management left its Aclaris Therapeutics share count unchanged in Q3 2026.
  • Aclaris Therapeutics made up 0.67% of RA Capital Management's portfolio in Q3 2026, its #32 holding.
  • RA Capital Management first reported a position in Aclaris Therapeutics in Q4 2015 and has held it in 16 quarters since.
  • RA Capital Management's Aclaris Therapeutics position peaked at $69.3M in Q4 2022.
  • 163 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q3 2026.

Based on RA Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.